AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...

AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for ...

It highlights that significant revenue is not expected until the second half of 2025, with a gradual launch anticipated for schizophrenia treatment ... While Bristol-Myers Squibb’s recent ...

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

The setback is a potential plus for Bristol Myers Squibb, which in September won Food and Drug Administration approval of Cobenfy, the first new kind of treatment for schizophrenia patients in decades ...

Shares of AbbVie (ABBV) are sinking on Monday after the company said two mid-stage trials of its investigative treatment for adults with schizophrenia ... stocks on TipRanks >> Read More on BMY: ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol ... Schizophrenia – A Network Meta-Analysis Current Estimates of the Incidence and Prevalence of Schizophrenia in the U.S. A full list of Bristol Myers ...

Bristol Myers Squibb (NYSE:BMY) said its newly approved schizophrenia therapy ... discontinuation rates due to treatment-related or treatment-emergent adverse events (TEAE) stood at 11% and ...

Shares of Bristol-Myers Squibb (BMY) are down today despite the drugmaker providing positive results for its schizophrenia ... 5 studies revealed that the treatment was generally well-tolerated ...

AbbVie (ABBV) shares dropped 11% premarket as late-stage trials for schizophrenia drug emraclidine did not meet primary ...

One of the bright spots for Bristol-Myers Squibb has been the approval of Cobenfy, a new treatment for schizophrenia. Analysts view this approval as a potential new growth driver for the company ...